ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0522

Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients
Abstract Number: 0523

Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity
Abstract Number: 0524

Development of Biomarker Models to Identify HLA-related Microbiome Associations in Anti-Ro+ Mothers of Children with Neonatal Lupus
Abstract Number: 0525

STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Abstract Number: 0526

Transcriptional Factor Profiling Denotes Specific Synovial Macrophage Heterogeneity
Abstract Number: 0527

Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Abstract Number: 0528

Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
Abstract Number: 0529

COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Abstract Number: 0530

Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
Abstract Number: 0531

Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Abstract Number: 0532

Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Abstract Number: 0533

Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase
Abstract Number: 0534

Lymphatic Dysfunction in Murine Lupus Photosensitivity
Abstract Number: 0535

Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Abstract Number: 0536

The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].